依马利尤单抗治疗巨噬细胞活化综合征的疗效与安全性
这项前瞻性单臂试验纳入14例继发于全身型幼年特发性关节炎或成人起病Still病、且既往大剂量糖皮质激素治疗失败的巨噬细胞活化综合征患者,接受依马利尤单抗联合背景糖皮质激素治疗。至第8周,14例中13例达到巨噬细胞活化综合征缓解,中位缓解时间25天;观察到病毒感染和病毒检测阳性。
要点
- 依马利尤单抗可快速中和干扰素γ活性,表现为血清CXCL9水平迅速下降。
- 14例中13例在第8周达到巨噬细胞活化综合征缓解,中位缓解时间25天。
- 治疗期间观察到病毒感染和病毒检测阳性,结论提出应筛查病毒感染,尤其巨细胞病毒。
核心结论
- 依马利尤单抗中和干扰素γ可有效诱导继发于全身型幼年特发性关节炎或成人起病Still病、且大剂量糖皮质激素治疗失败患者的巨噬细胞活化综合征缓解。
- 结论提出应进行病毒感染筛查,尤其针对巨细胞病毒。
研究设计与样本
- 前瞻性单臂试验,纳入继发于全身型幼年特发性关节炎或成人起病Still病、既往大剂量糖皮质激素治疗失败(联用或不联用阿那白滞素和/或环孢素)的巨噬细胞活化综合征患者。
- 依马利尤单抗为人抗干扰素γ抗体,与背景糖皮质激素联合给药;研究预设4周治疗,可根据研究者对疗效的评估缩短或延长。
- 患者随后进入为期12个月的长期随访研究;试验注册号为NCT02069899和NCT03311854。
主要发现
- 14例患者接受了依马利尤单抗治疗,全部完成试验并进入长期随访,随访结束时均存活。
- 所研究的给药方案(初始负荷剂量后给予维持剂量)是适当的,表现为干扰素γ活性被快速中和,血清C-X-C基序趋化因子配体9(CXCL9)水平迅速下降。
- 至第8周,14例中13例达到巨噬细胞活化综合征缓解,中位缓解时间为25天。
- 观察到病毒感染和病毒检测阳性。
关键数值与推荐
- 疗效结局为第8周时基于临床和实验室标准的巨噬细胞活化综合征缓解。
- 至第8周,14例中13例达到巨噬细胞活化综合征缓解,中位缓解时间25天。
临床怎么用
- 依马利尤单抗与背景糖皮质激素联合用于继发于全身型幼年特发性关节炎或成人起病Still病、大剂量糖皮质激素治疗失败的巨噬细胞活化综合征患者。
- 研究预设4周治疗,可根据研究者对疗效的评估缩短或延长。
- 结论提出应进行病毒感染筛查,尤其针对巨细胞病毒。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Macrophage activation syndrome (MAS) is a severe, life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD). The objective of this study was to confirm the adequacy of an emapalumab dosing regimen in relation to interferon-γ (IFNγ) activity by assessing efficacy and safety. The efficacy outcome was MAS remission by week 8, based on clinical and laboratory criteria. METHODS: We studied emapalumab, a human anti-IFNγ antibody, administered with background glucocorticoids, in a prospective single-arm trial involving patients who had MAS secondary to sJIA or AOSD and had previously failed high-dose glucocorticoids, with or without anakinra and/or ciclosporin. The study foresaw 4-week treatment that could be shortened or prolonged based on investigator's assessment of response. Patients entered a long-term (12 months) follow-up study. RESULTS: Fourteen patients received emapalumab. All patients completed the trial, entered the long-term follow-up and were alive at the end of follow-up. The investigated dosing regimen, based on an initial loading dose followed by maintenance doses, was appropriate, as shown by rapid neutralisation of IFNγ activity, demonstrated by a prompt decrease in serum C-X-C motif chemokine ligand 9 (CXCL9) levels. By week 8, MAS remission was achieved in 13 of the 14 patients at a median time of 25 days. Viral infections and positive viral tests were observed. CONCLUSIONS: Neutralisation of IFNγ with emapalumab was efficacious in inducing remission of MAS secondary to sJIA or AOSD in patients who had failed high-dose glucocorticoids. Screening for viral infections should be performed, particularly for cytomegalovirus. TRIAL REGISTRATION NUMBER: NCT02069899 and NCT03311854.
引用
- De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023. PMID: 37001971. doi:10.1136/ard-2022-223739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。